Randomised clinical trial: Identification of responders to short-term treatment with esomeprazole for dyspepsia in primary care - A randomised, placebo-controlled study

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 1, 2011, Pages 41-49

  Meineche Schmidt, V ^a   Christensen, E ^b   Bytzer, P ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DRUG EFFICACY; DYSPEPSIA; FEMALE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATIETY; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; UPPER GASTROINTESTINAL TRACT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; DYSPEPSIA; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PRIMARY HEALTH CARE; PROTON PUMP INHIBITORS; REGRESSION ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650028813     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04501.x     Document Type: Article

References (23)

1. Talley NJ, Vakil NB, Moayyedi P,. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 1756-80.
2. Veldhuyzen van Zanten S, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Can Med Assoc J 2000; 162 (12 Suppl): S3-23.
3. Talley NJ, Vakil N, Delaney B, et al. Management issues in dyspepsia: current consensus and controversies. Scand J Gastroenterol 2004; 39: 913-8.
4. Folkersen BH, Larsen B, Qvist P,. General practitioners' handling of patients with dyspepsia. Ugeskr Laeger 1997; 159: 3777-81.
5. Voutilainen M, Mantynen T, Kunnamo I, et al. Impact of clinical symptoms and referral volume on endoscopy for detecting peptic ulcer and gastric neoplasms. Scand J Gastroenterol 2003; 38: 109-13.
6. Muris JW, Starmans R, Fijten GH, et al. Abdominal pain in general practice. Fam Pract 1993; 10: 387-90.
7. Meineche-Schmidt V,. Empiric treatment with high and standard dose of omeprazole in general practice: two-week randomized placebo-controlled trial and 12-month follow-up of health-care consumption. Am J Gastroenterol 2004; 99: 1050-8.
8. Meineche-Schmidt V,. Classification of dyspepsia and response to treatment with proton-pump inhibitors. Aliment Pharmacol Ther 2004; 20: 1171-9.
9. Meineche-Schmidt V, Christensen E,. Which dyspepsia patients will benefit from omeprazole treatment? Analysis of a Danish multicenter trial. Am J Gastroenterol 2000; 95: 2777-83.
10. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl. II): 37-42.
11. Meineche-Schmidt V, Christensen E,. Classification of dyspepsia. Identification of independent symptom components in 7270 consecutive, unselected dyspepsia patients from general practice. Scand J Gastroenterol 1998; 33: 1262-72.
12. Meineche-Schmidt V, Krag E,. Antisecretory therapy in 1017 patientswith ulcerlike or refluxlike dyspepsia in general practice. Eur J Gen Pract 1997; 3: 125-30.
13. Armitage P, Berry G,. Statistical Methods in Medical Research. Oxford: Blackwell Scientific Publications, 1994.
14. Reimer C, Søndergaard B, Hilsted L, et al. Proton pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137: 80-7.
15. Gillen D, Wirz A, McColl KEL,. Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. Gastroenterology 2004; 126: 980-8.
16. Grudell AB, Camilleri M, Burton DD, et al. Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study. Aliment Pharmacol Ther 2006; 24: 1037-43.
17. Verkijk M, Gielkens HA, Lamers CB, et al. Effect of gastrin on antroduodenal motility: role of intraluminal acidity. Am J Physiol 1998; 275: G1209-16.
18. Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, et al. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol 2005; 100: 1477-88.
19. Van Zanten SV, Flook N, Talley NJ, et al. One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: a randomized, placebo-controlled study. Aliment Pharmacol Ther 2007; 26: 665-72.
20. Bolling-Sternevald E, Lauritsen K, Talley NJ, et al. Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? Aliment Pharmacol Ther 2003; 18: 117-24.
21. Talley NJ, Vakil N, Lauritsen K, et al. Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response? Aliment Pharmacol Ther 2007; 26: 673-82. (Pubitemid 47246199)
22. Bytzer P,. Assessment of reflux symptom severity: methodological options and their attributes. Gut 2004; 53 (Suppl. 4): IV28-34.
23. Talley NJ, Armstrong D, Junghard O, et al. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2006; 24: 371-6.